Drug Profile
Cannabidiol - MMJ PhytoTech
Alternative Names: PTL101Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator MMJ PhytoTech
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-II for Epilepsy (Adjunctive treatment, In adolescents, In children, Treatment-resistant) in Israel (PO) (PhytoTech Therapeutics website, February 2022)
- 24 Jul 2018 Final efficacy data from a phase II trial in Epilepsy released by Harvest One Cannabis
- 28 Jun 2018 PhytoTech Therapeutics completes a phase II trial in Epilepsy (Adjunctive treatment, Treatment-resistant, In adolescents, In children) in Israel (PO) (NCT02987114)